Pulmonary hypertension screening: Difference between revisions
Rim Halaby (talk | contribs) |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Patients with a known [[BMPR2]] [[mutation]], [[scleroderma]], and [[portal hypertension]] undergoing evaluation for [[liver transplantation]] should receive periodic screening | Patients with a known [[BMPR2]] [[mutation]], [[scleroderma]], and [[portal hypertension]] undergoing evaluation for [[liver transplantation]] should receive periodic screening through a thorough assessment of the presence of symptoms, physical examination, [[chestX ray]], as well as [[elctrocardiography]]. Patients with [[HIV]] infection should not be screened for PH in the absence of any suggestive findings.<ref>ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension</ref> | ||
==Screening== | ==Screening== | ||
Revision as of 20:56, 28 August 2014
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension screening On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension screening |
|
Risk calculators and risk factors for Pulmonary hypertension screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assistant Editor(s)-in-Chief: Ralph Matar
Overview
Patients with a known BMPR2 mutation, scleroderma, and portal hypertension undergoing evaluation for liver transplantation should receive periodic screening through a thorough assessment of the presence of symptoms, physical examination, chestX ray, as well as elctrocardiography. Patients with HIV infection should not be screened for PH in the absence of any suggestive findings.[1]
Screening
Patients who are considered at high risk for the development of pulmonary hypertension and require periodic screening include:
- Those with a known BMPR2 mutation (associated with familial pulmonary hypertension).
- Those with Scleroderma spectrum of diseases.
- Those with portal hypertension who are undergoing evaluation for liver transplantation.
The best study for screening patients suspected of having pulmonary hypertension based on history, physical examination, chest x-ray (CXR), and electrocardiogram (ECG) is an Echocardiogram.
These are the parameters that should be evaluated on Echocardiogram:
- Right atrial and right ventricular enlargement.
- Reduced right ventricular function.
- Displacement of the interventricular septum.
- Tricuspid regurgitation(TR).
- Tei index or myocardial performance index (measured by Doppler ultrasound).
- Pericardial effusion (presence also indicates a higher mortality rate).
The Tei index is an index of combined right ventricular systolic and diastolic function obtained by dividing the sum of both isovolumetric contraction and relaxation intervals by the ejection time.
References
- ↑ ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension